Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01599962

Acronym

Mira-Basel

Enrollment

Registered

2012-05-16

Start date

2012-03-31

Completion date

2012-08-31

Last updated

2012-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Memory Functions

Brief summary

To investigate the effects of the calcimimetic agent cinacalcet on cognitive functions in healthy humans.

Interventions

DRUGCinacalcet

single administration, 90mg

DRUGPlacebo

single administration

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy * normotensive * native or fluent German-speaking * caucasian (European ancestry) * BMI between 19 and 27 kg/m2

Exclusion criteria

* acute or chronic psychiatric or somatic disorder * pathological ECG * Low serum calcium * known hypersensitivity to the IMP * pregnancy * breast-feading * long-term medication within last 3 months * smoking more than 3 cigarettes per day * seizures in participants and first degree relatives * concurrent participation in another study

Design outcomes

Primary

Measure	Time frame
Change of attention functions under cinacalcet	two study days within 10 days
Change of memory functions under cinacalcet	two testing days within 10 days

Secondary

Measure	Time frame
Change of emotional state under cinacalcet	two study days within 10 days

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026